Treatments of Cancers    

FOI REFERENCE:24002

FOI TITLE: Treatments of Cancers    

FOI DATE: 2^nd April 2024  

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine		Number patients treated
1.1 Abemaciclib (Verzenios)		68
1.2 Alpelisib (Piqray)		0
1.3 Fulvestrant (fulvestrant or Faslodex)		33
1.4 Palbociclib (Ibrance)		74
1.5 Ribociclib (Kisqali)		*

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Number patients treated

55

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Treatment intent		Number patients treated
3.1 Curative		57
3.2 Palliative		11
3.3 Not known / stated		0

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of combination or monotherapy		Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)		17
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)		20
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)		0

PROSTATE CANCER

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine		Number patients treated
5.1 Abiraterone (Zytiga or generic abiraterone)		47
5.2 Apalutamide (Erleada)		36
5.3 Cabazitaxel (Jevtana or generic cabazitaxel)		11
5.4 Darolutamide (Nubeqa)		19
5.5 Enzalutamide (Xtandi)		171

Q6. How many patients were treated with docetaxel specifically for prostate cancer (ICD-10 code = C61) in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine		Number patients treated
Docetaxel		0

Q7. How many patients were treated with the following medicine combinations in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine		Number patients treated
7.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy		0
7.2 Apalutamide (Erleada) + Androgen Deprivation Therapy		0
7.3 Darolutamide (Nubeqa) + Docetaxel + ADT		13
7.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy		0

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

OVARIAN and CANCERS

Q8. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine		Number patients treated
8.1 Dostarlimab (Jemperli)		0
8.2 Niraparib (Zejula)		10
8.3 Rucaparib (Rubraca)		6

Q9. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine		Number patients treated
9.1 Olaparib in total		7
9.2 Olaparib monotherapy		7
9.3 Olaparib + bevacizumab in combination		*
9.4 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin		17

Q10. How many patients were treated for endometrial cancer with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine		Number patients treated
10.1 Dostarlimab monotherapy		0
10.2 Dostarlimab + platinum-based chemotherapy, or dostarlimab + carboplatin and paclitaxel		0
10.3 Pembrolizumab (Keytruda) in total		6
10.4 Lenvatinib (Lenvima) in total		0
10.5 Pembrolizumab monotherapy		*
10.6 Pembrolizumab + Lenvatinib (Lenvima) in combination		5

*This relates to low numbers between 1 and 4. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018